Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-15T05:29:21.741Z Has data issue: false hasContentIssue false
  • English
  • Français

Infection Control in Gene Therapy

Published online by Cambridge University Press:  02 January 2015

Martin E. Evans and
Judith A. Lesnaw
Martin E. Evans*
Affiliation:
University of Kentucky Medical Center, T.H. Morgan School of Biological Sciences, University of Kentucky, Lexington, Kentucky
Judith A. Lesnaw
Affiliation:
Division of Molecular and Cell Biology, T.H. Morgan School of Biological Sciences, University of Kentucky, Lexington, Kentucky
*
HG608 UKMC, 800 Rose St, Lexington, KY 40536-0293
Get accessRights & Permissions [Opens in a new window]

Abstract

Gene therapy is now being studied for the treatment of a wide variety of acquired and inherited diseases. Viruses used as vectors for gene transfer include retroviruses, adenoviruses, vaccinia viruses, adeno-associated viruses, and herpesviruses. These vectors, developed in the laboratory and in animal studies, are now being introduced into the clinical arena. Infection control practitioners will be involved invariably in reviewing the use of these agents in their clinics and hospitals. This review summarizes key aspects of the more common vectors and makes recommendations for infection control.

Information

Type
Emerging Infectious Diseases
Information
Infection Control & Hospital Epidemiology , Volume 20 , Issue 8 , August 1999, pp. 568 - 576
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. National Institutes of Health. Office of Recombinant DNA Activities. Documents—recombinant DNA Protocol list (in Adobe Acrobat PDF); protocol list table (PDF), http://www.nih.gov/od/orda/docs.htm.Google Scholar
2. The Journal of Gene Medicine Website. Clinical trials—charts and statistics, updated March 1, 1999. Gene therapy vectors. http://www.wiley.co.uk/genetherapy/clinical/vectors/html.Google Scholar
3.Fraser, MJ. The baculovirus-infected insect cell as a eukaryotic gene expression system. In: Muzyczka, N, ed. Viral Expression Vectors. Berlin, Germany: Springer-Verlag; 1992:131–172.CrossRefGoogle Scholar
4.Margolskee, RF. Epstein-Barr virus based expression vectors. In: Muzyczka, N, ed. Viral Expression Vectors. Berlin, Germany: Springer-Verlag; 1992:67–96.CrossRefGoogle Scholar
5.Weichselbaum, RR, Kufe, D. Gene therapy of cancer. Lancet 1997;349(suppl II):10–12.CrossRefGoogle ScholarPubMed
6.Poeschla, E, Corbeau, P, Wong-Staal, F. Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 1996;93:11395–11399.Google Scholar
7.Kafri, T, van Praag, H, Ouyang, L, Gage, FH, Verma, IM. A packaging cell line for lentivirus vectors. J Virol 1999;73:576–584.Google Scholar
8.Roth, JA, Cristiano, RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21–39.CrossRefGoogle ScholarPubMed
9.Knoell, DL, Yiu, IM. Human gene therapy for hereditary diseases: a review of trials. Am J Health SystPkarm 1998;55:899–904.Google Scholar
10. National Institutes of Health, Office of Recombinant DNA Activities. Guidelines for research involving recombinant DNA molecules, May 1998. Appendix B: classification of human etiologic agents on the basis of hazard, http://www.nih.gov/od/orda/toc.htm.Google Scholar
11.Steinberg, MH. Human gene therapy: the future is now, the promise yet to come. Blood Cells 1991;17:417–424.Google Scholar
12.Robbins, PD, Tahara, H, Ghivizzani, SC. Viral vectors for gene therapy. Trends Biotechnol 1998;16:35–40.Google Scholar
13.Weiss, RA. Retrovirus classification and cell interactions. J Antimicrob Chemother 1996;37(suppl B):1–11.Google Scholar
14.Miller, AD. Retroviral vectors. In: Muzyczka, N, ed. Viral Expression Vectors. Berlin, Germany: Springer-Verlag; 1992:1–19.Google Scholar
15.Moen, RC. Directions in gene therapy. Blood Cells 1991;17:407–416.Google Scholar
16.Zufferey, R, Dull, T, Mandel, RJ, Bukovsky, A, Quiroz, D, Naldini, L, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998;72:9873–9880.Google Scholar
17.Miyoshi, H, Smith, KA, Mosier, DE, Verma, IM, Torbett, BE. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999;283:682–686.Google Scholar
18.Kohn, DB. Gene therapy for hematopoetic and immune disorders. Bone Marrow Transplant 1996;18(suppl 3):S55–S58.Google Scholar
19.Kohn, DB, Parkman, R. Gene therapy for newborns. FASEB J 1997;11:635–639.CrossRefGoogle ScholarPubMed
20.Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens (29 CFR 1910.1030). Federal Register December 6, 1991;56:64003–64182.Google Scholar
21.Bolyard, EA, Tablan, OC, Williams, WW, Pearson, ML, Shapiro, CN, Deitchman, SD, et al. Guideline for infection control in healthcare personnel, 1998. Infect Control Hosp Epidemiol 1998;19:407–463.CrossRefGoogle ScholarPubMed
22.Horwitz, MS. Adenoviridae and their replication. In: Fields, BN, Knipe, DM, eds. Fields Virology, vol 2. 2nd ed. New York, NY: Raven Press; 1990:1679–1721.Google Scholar
23.Khoo, SH, Bailey, AS, de Jong, JC, Mandal, BK. Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology. J Infect Dis 1995;172:629–637.Google Scholar
24.Brummitt, CF, Cherrington, JM, Katzenstein, DA, Juni, BA, van Drunen, N, Edelman, C, et al. Nosocomial adenovirus infections: molecular epidemiology of an outbreak due to adenovirus 3a. J Infect Dis 1988;158:423–432.Google Scholar
25.Horwitz, MS. Adenoviruses. In: Fields, BN, Knipe, DM, eds. Fields Virology, vol 2. 2nd ed. New York, NY: Raven Press; 1990:1723–1740.Google Scholar
26.Fox, JP, Hall, CE, Cooney, MK. The Seattle virus watch, VII: observations on adenovirus infections. Am J Epidemiol 1977;105:362–386.CrossRefGoogle ScholarPubMed
27.Singh-Naz, N, Brown, M, Ganeshananthan, M. Nosocomial adenovirus infection: molecular epidemiology of an outbreak. Pediatr Infect Dis J 1993;12:922–925.Google Scholar
28.Porter, JDH, Teter, M, Traister, V, Pizzuitti, W, Parkin, WE, Farrell, J. Outbreak of adenoviral infections in a long-term paediatric facility, New Jersey, 1986/87. J Hosp Infect 1991;18:201–210.Google Scholar
29.Straube, RC, Thompson, MA, Van Dyke, RB, Wadell, G, Connor, JD, Wingard, D, et al. Adenovirus type 7b in a children's hospital. J Infect Dis 1983;147:814–819.Google Scholar
30.Krilov, LR, Rubin, LG, Frogel, M, Gloster, E, Ni, K, Kaplan, M, et al. Disseminated adenovirus infection with hepatic necrosis in patients with human immunodeficiency virus infection and other immunodeficiency states. Rev Infect Dis 1990;12:303–307.Google Scholar
31.Yagisawa, T, Takahashi, K, Yamaguchi, Y, Teraoka, S, Horita, S, Toma, H, et al. Adenovirus induced nephropathy in kidney transplant recipients. Transplant Proc 1989;21:2097–2099.Google Scholar
32.Michaels, MG, Green, M, Wald, ER, Starzl, TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992;165:170–174.Google Scholar
33.McGrath, D, Falagas, ME, Freeman, R, Rohrer, R, Fairchild, R, Colbach, C, et al. Adenovirus infection in adult orthotopic liver transplant recipients: incidence and clinical significance. J Infect Dis 1998;177:459–462.CrossRefGoogle ScholarPubMed
34.Hierholzer, JC. Adenovirus in the immunocompromised host. Clin Microbiol Rev 1992;5:262–274.CrossRefGoogle ScholarPubMed
35.Buchdahl, RM, Taylor, P, Warner, JD. Nebulised ribavirin for adenovirus pneumonia. Lancet 1985;2:1070–1071.Google Scholar
36.Cassano, WF. Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1991;7:247–248.Google Scholar
37.Stratford-Perricaudet, LD, Briand, P, Perricaudet, M. Feasibility of aden-ovirus-mediated gene transfer in vivo. Bone Marrow Transplant 1992;9(suppl 1):151–152.Google Scholar
38.Spergel, JM, Hsu, W, Akira, S, Thimmappaya, B, Kishimoto, T, Chen-Kiang, S. NF-IL6, a member of the C/EBP family, regulates ElA-responsive promoters in the absence of E1A. J Virol 1992;66:1021–1030.Google Scholar
39.Yang, Y, Nunes, FA, Berrensci, K, Gonczol, E, Engelhardt, JF, Wilson, JM. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994;7:362–369.Google Scholar
40.Crystal, RG, McElvaney, NG, Rosenfeld, MA, Chu, CS, Mastrangeli, A, Hay, JG, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42–51.Google Scholar
41.Goodman, JC, Trask, TW, Chen, SH, Woo, SL, Grossman, RG, Carey, KD, et al. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic gancyclovir: pathologic, radiologic, and molecular studies. Hum Gene Ther 1996;7:1241–1250.Google Scholar
42.Bellon, G, Michel-Calemard, L, Thouvenot, D, Jagneaux, V, Poitevin, F, Malcus, C, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997;8:15–25.Google Scholar
43.Imler, JL, Bout, A, Dreyer, D, Dieterle, ASchultz, H, Valerio, D, et al. Trans-complementation of El-deleted adenovirus: a new vector to reduce the possibility of co-dissemination of wild-type and recombinant adenoviruses. Hum Gene Ther 1995;6:711–721.Google Scholar
44.Tevethia, MJ, Spector, DJ, Leisure, KM, Stinski, MF. Participation of two human cytomegalovirus early gene regions in transcriptional activation of adenovirus promoters. Virology 1987;161:276–285.Google Scholar
45.Phelps, WC, Yee, CL, Munger, K, Howley, PM. The human papilloma virus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 1988;53:539–547.Google Scholar
46.Warren, D, Nelson, KE, Farrar, JAHurwitz, E, Hierholzer, J, Ford, E, et al. A large outbreak of epidemic keratoconjuctivitis: problems in controlling nosocomial spread. J Infect Dis 1989;160:938–947.Google Scholar
47.Centers for Disease Control. Epidemic keratoconjunctivitis in an ophthalmology clinic—California. MMWR 1990;39:598–601.Google Scholar
48.Jernigan, JALowry, BS, Hayden, FG, Kyger, SAConway, BP, Groschel, DHM, et al. Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: risk factors and control. J Infect Dis 1993;167:1307–1313.Google Scholar
49. Finn A Anday, E, Talbot, GH. An epidemic of adenovirus 7a infection in a neonatal nursery: course, morbidity, and management. Infect Control Hosp Epidemiol 1988;9:398–404.Google Scholar
50.Centers for Disease Control. Vaccinia (smallpox) vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40(RR-14):1–10.Google Scholar
51.Centers for Disease Control. Contact spread of vaccinia from a National Guard vaccinee—Wisconsin. MMWR 1985;34:182–183.Google Scholar
52.Cooney, EL, Collier, AC, Greenberg, PD, Coombs, RW, Zarling, J, Arditti, DE, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Ixincet 1991;337:567–572.Google Scholar
53.Lane, JM, Ruben, FL, Neff, JM, Millar, JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970;122:303–309.Google Scholar
54.Centers for Disease Control. Vaccinia outbreak—Newfoundland. MMWR 1981;36:453–455.Google Scholar
55.Centers for Disease Control. Vaccinia outbreak—Nevada. MMWR 1983;32:403–404.Google Scholar
56.Centers for Disease Control. Contact spread of vaccinia from a recently vaccinated Marine—Louisiana. MMWR 1984;33:37–38.Google Scholar
57.Moss, B. Poxvirus expression vectors. In: Muzyczka, N, ed. Viral Expression Vectors. Berlin, Germany: Springer-Verlag; 1992:25–38.Google Scholar
58.Buller, RM, Smith, GL, Cremer, K, Notkins, AL, Moss, B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985;317:813–815.CrossRefGoogle ScholarPubMed
59.Lattime, EC, Lee, SS, Eisenlohr, LC, Mastrangelo, MJ. In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol 1996;23:88–100.Google Scholar
60.Mastrangelo, MJ, Macguire, HC Jr., McCue, P, Lee, SS, Alexander, A, Nazarian, LN, et al. A pilot study demonstrating the feasibility of using intratumoral vaccinia injections as a vector for gene transfer. Vaccine Research 1995;4:55–69.Google Scholar
61.Tsang, KY, Zaremba, S, Nieroda, CAZhu, MZ, Hamilton, JM, Schlom, J. Generation of human cytotoxic T cells specific for human carcinoem-bryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Institute 1995;87:982–990.Google Scholar
62.Boursnell, MEG, Rutherford, E, Hickling, JK, Rollinson, EAMunro, AJ, Rolley, N, et al. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996;14:1485–1494.Google Scholar
63.Downie, AW. Poxvirus group. In: Horsfall, FL Jr, Tamm, I, eds. Viral and Rickettsial Infections of Man. 4th ed. Philadelphia, PA: JB Lippincott Company; 1965:953–960.Google Scholar
64.Baxby, D. Poxviruses. In: Belsche, RB, ed. Textbook of Human Virology. Littleton, MA: PSG Publishing Co, Inc; 1984:929–950.Google Scholar
65.Muzyczka, N. Use of adeno-associated virus as a general transduction vector for mammalian cells. In: Muzyczka, N, ed. Viral Expression Vectors. Berlin, Germany: Springer-Verlag; 1992:97–129.Google Scholar
66.American College of Physicians. Guide for Adult Immunization. 3rd ed. Philadelphia, PA: American College of Physicians; 1994.Google Scholar
67.Corey, L, Spear, PG. Infections with herpes simplex viruses, (part I). N Engl J Med 1986;314:686–691.CrossRefGoogle Scholar
68.Hirsch, M. Herpes simplex virus. In: Mandell, GL, Bennett, JE, Dolin, R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995:1336–1345.Google Scholar
69.Corey, L, Spear, PG. Infections with herpes simplex viruses (part II). N Engl J Med 1986;314:749–757.Google Scholar
70.Adler, SP. Herpes simplex. In: Mayhall, CG, ed. Hospital Epidemiology and Infection Control. Baltimore, MD: Williams & Wilkins; 1996:437–440.Google Scholar
71.Centers for Disease Control and Prevention. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996;17:53–80.Google Scholar